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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanBackground: Acinetobacter baumannii is one of the most important nosocomial pathogens
worldwide. This study aimed to use multilocus sequence typing (MLST) for the epidemiological
surveillance of A. baumannii isolates in Taiwan and analyze the clinical presentations and pa-
tients’ outcome.
Methods: MLST according to both Bartual’s PubMLST and Pasteur’s MLST schemes was applied
to characterize bloodstream imipenem-resistant A. baumannii (IRAB) infection in intensive
care units in a medical center. A total of 39 clinical IRAB bloodstream isolates in 2010 were
enrolled. We also collected 13 imipenem-susceptible A. baumannii (ISAB) bloodstream isolates
and 30 clinical sputum isolates (24 IRAB and 6 ISAB) for comparison. Clinical presentations and
outcome of the patients were analyzed.
Results: We found that infection by ST455B/ST2P and inappropriate initial therapy were statis-
tically significant risk factors for mortality. More than one-third of the IRAB isolates belonged
to ST455B/ST2P. Most ST455B/ST2P (80%) carried ISAba1eblaOXA-23, including 10 (66.7%) with
Tn2006 (ISAba1eblaOXA-23eISAba1) in an AbaR4-type resistance island. ST455
B/ST2P appears
to evolve from ST208B/ST2P of clonal complex (CC) 92B/CC2P. In this hospital-based study,
A. baumannii ST455 accounted for 38.5% of IRAB bacteremia, with a high mortality of 86.7%.Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Children’s Hospital, Number 5,
n, Taiwan.
.org.tw (C.-H. Chiu).
.03.003
Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Emergence of imipenem-resistant A. baumannii ST455 589Approximately 85% of ST455B/ST2Pbacteremia had a primary source of ventilation-associated
pneumonia.
Conclusion: We report the emergence in Taiwan of IRAB ST455B/ST2P, which is the current pre-
dominant clone of IRAB in our hospital and has been causing bacteremia with high mortality in
critical patients.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii is one of the most important
nosocomial pathogens worldwide, causing bacteremia,
pneumonia, urinary tract infection, soft tissue infection, or
intra-abdominal infection in hospitalized patients.1
Bacteremia caused by imipenem-resistant A. baumannii
(IRAB) has been associated with a higher mortality (46.0%)
than bacteremia by imipenem-susceptible A. baumannii
(ISAB; 28.3%) and other diagnoses of A. baumannii infec-
tion.2 The most common source of A. baumannii infection
was the respiratory tract,1 but the relationship between
respiratory tract infection and IRAB bacteremia remains
unknown.
Multilocus sequence typing (MLST) is a widely used
technique for bacterial typing, proven to provide unam-
biguous typing data for long-term and global A. baumannii
epidemiological surveillance.3 Two MLST schemes, Bartual’s
PubMLST and Pasteur’s MLST schemes, were available in
delineating the population structure of A. baumannii.3e6
However, there have been no published Bartual’s MLST
data in clinical A. baumannii isolates in Taiwan.
This study, using MLST, was designed to characterize
bloodstream IRAB infection of intensive care unit (ICU)
patients in 2010 in a single medical center. We compared
the result with those from bloodstream ISAB, and also IRAB
and ISAB from sputum of patients with clinically confirmed
ventilation-associated pneumonia (VAP).
Materials and methods
Study participants and inclusion criteria
This study was approved by the Institutional Review Board
(100-3592B) of Chang Gung Memorial Hospital, Taoyuan,
Taiwan. Charts were reviewed for ICU patients who were
treated in Chang Gung Memorial Hospital in 2010 and had
VAP  1 positive blood or sputum culture for A. baumannii,
and symptoms and signs of infection. For patients with
multiple episodes, only the first episode was included. Pa-
tients with incomplete medical records, younger than 18
years of age, or with polymicrobial infection were
excluded.
Clinical data collection and definitions
Clinical data were retrospectively collected. VAP was
defined as pneumonia with pulmonary infiltrates on chestradiographs, purulent tracheal secretions not less than 48
hours after intubation, and the start of mechanical venti-
lation7,8 “VAP as a primary source” was defined by the
condition when at least one A. baumannii sputum isolate
was found from patients with VAP prior to the development
of bacteremia, which was proven via the isolation of an A.
baumannii in blood. Mortality was defined as infection-
attributable death, wherein the criteria of death were
met before the symptoms and signs of bacteremia or
pneumonia were resolved and with at least a blood or
sputum culture positive for A. baumannii.9 Appropriate
antimicrobial therapy was defined as administering patients
with at least one antimicrobial agent, except aminoglyco-
side, susceptible in vitro, within 2 days after bacteremia
onset.10 Culture detecting time was the interval (days)
from culture sampling to reporting.
Bacterial isolates and antimicrobial susceptibility
Conventional biochemical tests and 16Se23S rRNA inter-
genic spacer region sequencing as described previously
were used to characterize bacterial genospecies.11 Anti-
microbial susceptibility was determined by the disk diffu-
sion method according to Clinical and Laboratory Standards
Institute standards.12 The minimum inhibitory concentra-
tion (MIC) of imipenem was further determined with Etest
(Biomerieux, La Balmes les Grottes, France). The break-
point for defining ISAB was an MIC of  4 mg/L, and a
breakpoint of  8 mg/L for IRAB, including both interme-
diately resistant and resistant strains.12 The tigecycline disk
diffusion breakpoints was based on the FDA criteria (sus-
ceptible:  16 mm; resistant:  12 mm).13
MLST
In order to survey clonal relationships, methods of Bartual’s
PubMLST and Pasteur’s MLST scheme were used.4,5 By Bar-
tual’s PubMLST method, seven standard housekeeping loci
[citrate synthase (gltA), gyrase B (gyrB), glucose dehydro-
genase B (gdhB), recombination A (recA), chaperone 60
(cpn60), glucose-6-phosphate isomerase (gpi), and RNA
polymerase (rpoD)] were checked.4 Sequences were
compared with the A. baumannii database at the MLST
database (http://pubmlst.org/abaumannii/) and conduct-
ed using BLAST. By the Pasteur’s MLST scheme (www.
pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.
html), internal fragments of seven housekeeping genes
[cpn60, protein elongation factor EF-G (fusA), gltA, CTP
synthase (pyrG), recA, 50S ribosomal protein L2 (rplB), and
590 H.-Y. Lee et al.RNA polymerase subunit B (rpoB)] were amplified and
sequenced for each isolate.5
The eBURST algorithm (http://eburst.mlst.net/) was
used to analyze the genetic relationships of sequence types
(STs).14 Clonal complexes (CCs) were stringently defined as
a cluster of STs having the same alleles at six among the
seven loci and containing at least two STs.14 Novel CCs were
named by STs of their founders.
Pulsed-field gel electrophoresis
Isolates were analyzed by pulsed-field gel electrophoresis
(PFGE) using methods as described elsewhere.15 The frag-
ment patterns obtained were interpreted as described by
Tenover et al.16 Briefly, isolates with no less than seven-
band difference were considered to be different geno-
types, which were arbitrarily designated in alphabetical
order. Isolates with identical fingerprints and less than two-
band difference were considered as the same genotype,
whereas those with two-band to six-band difference were
considered as subtypes of an existing genotype.
Polymerase chain reaction and sequencing
Primers specific for imipenem resistance genes (blaOXA-23,
blaOXA-40, blaOXA-54, blaOXA-58, blaOXA-51, blaADC, blaIMP-1,
blaIMP-2, blaVIM-1, blaVIM-2, and blaNDM-1), insertion se-
quences (ISAba1, ISAba2, ISAba3, ISAba4, and IS1008), and
the AbaR4-type islands were designed, and polymerase
chain reaction amplification and sequence determination
were performed as described previously.17e19
Statistical analysis
Data analyses were performed using the SPSS software,
version 17.0 (SPSS Inc., Chicago, IL, USA). We used Student
t test, Chi-square test, or Fisher’s exact test when appro-
priate to compare proportions. Variables with p < 0.2 in the
univariate analysis were added in a forward stepwise
manner and selected to create the final model for multi-
variable analysis. All statistical analyses were two-sided,
and significance was set at p < 0.05.
Results
Clinical isolates
A total of 39 clinical IRAB bloodstream isolates in 2010 met
the inclusion criteria and were enrolled in this cohort study
(Table 1). For comparison, 13 ISAB bloodstream isolates and
30 clinical sputum isolates (24 IRAB and 6 ISAB) fitting
the inclusion criteria were also randomly collected
(Tables 1 and 2).
STs, antimicrobial susceptibilities, and PFGE
genotypes
There were 26 novel STs according to Bartual’s PubMLST
scheme in this study, including ST455, ST456, ST544eST556,
and ST673eST683. These novel STs were newly found inChang Gung Memorial Hospital, and registered in the
following web site (id Z number of STs): http://pubmlst.
org/. Most IRAB isolates (38.5% from bloodstream and
45.8% from sputum) belonged to ST455. ST455 isolates were
susceptible to colistin (100%) and tigecycline (66.7%), but
86.7% were resistant to ampicillinesulbactam and 100%
were resistant to all other antibiotics tested.
Most IRAB isolates belonged to CC92 and CC455 (blood-
stream: CC455 48.7%, CC92 28.2%; sputum: CC455 62.5%,
CC92 20.8%). In contrast to IRAB, few ISAB isolates (15.4%
from bloodstream and 16.7% sputum) belonged to CC92 and
no ISAB was in CC455. STs of ISAB were so diverse that 13
bloodstream isolates belonged to 11 different STs and six
sputum isolates belonged to six different STs.
No difference was found in the ratio of ST455 among
IRAB isolated from blood and sputum (15/39 vs. 11/24,
p Z 0.564). Similar results were also found in all other STs
(all p > 0.05).
More than half of the IRAB clinical isolates were found in
the main evolutionary tract of CC92 to the novel CC455,
descending from the founder ST208 to ST544, and then to
ST455 (Figure 1). It is notable that the attributable mor-
tality in patients infected by these STs appeared higher and
higher along the evolution (ST208: 33.3%; ST544: 75%;
ST455: 86.7%); however, this should be evaluated further.
ST544 is a one-locus variant of ST455 and a two-locus
variant of ST92 (1-3-3-2-2-7-3). ST544, therefore,
belonged to CC455 but not CC92.
By contrast, among the 39 IRAB isolates, 34 isolates
(87.2%) belonged to ST2, three (7.7%) to ST129, one (2.6%)
to ST217, and one (2.6%) to novel STN1 (Table 1) according
to Pasteur’s MLST scheme.
Based on Tenover’s criteria,16 the 39 bloodstream IRAB
isolates included 15 different PFGE genotypes and their
subtypes. Sixty percent (9/15) ST455B and 50% (17/34) ST2P
belonged to PFGE genotype 1 or its seven subtypes.Imipenem resistance genes
For a total of 82 isolates, all isolates carried blaOXA-51-like.
The blaOXA-23 gene (GenBank accession no. GQ861439.1)
was found in 54 isolates (65.9%, 54/82). The blaOXA-58 gene
appeared in three isolates.
Among the 39 bloodstream IRAB isolates, the upstream
ISAba1 was found in seven (17.9%) with blaOXA-51-like and in
25 (64.1%) with blaOXA-23 including 18 with Tn2006 (ISA-
ba1eblaOXA-23eISAba1) in an AbaR4-type resistance island
and seven with Tn2008 (ISAba1eblaOXA-23) (Table 1). All of
these isolates showed high-level resistance to imipenem
(all MIC >32 mg/L). Two isolates (ST455 and ST208) carried
blaIMP-1. None carried blaOXA-40/blaOXA-24, blaIMP-2, blaVIM-1,
blaVIM-2, blaNDM-1, blaADC, ISAba2, IS1008, or Tn2007 (ISA-
ba4eblaOXA-23).
Among the 24 IRAB isolates from sputum, the upstream
ISAba1 was found in two isolates (8.3%) with blaOXA-51-like
and in 20 (83.3%) with blaOXA-23, including 18 Tn2006 (ISA-
ba1eblaOXA-23eISAba1) in an AbaR4-type resistance island
and two Tn2008 (ISAba1eblaOXA-23) (Table 2). All of these
isolates showed high-level resistance to imipenem (all MIC
>32 mg/L). Tn2007 (ISAba4eblaOXA-23) was not found in
these isolates. The upstream ISAba3 was found in one
Table 1 Sequence types (ST), allelic profiles, clonal complex (CC), imipenem resistance genes, primary source of infection, and attributable mortality of Acinetobacter
baumannii derived from patients with IRAB bacteremia (the upper part) or ISAB bacteremia (the lower part).
ST Bartual’s PubMLST
Allelic profiles
CC No. of isolates Carbapenem resistance genes VAP as a source Mortality
MLST (B/P) Tn2006 Tn2008 ISAba1eblaOXA-51 ISAba3eblaOXA-58eISAba3 blaIMP
IRAB
455/2 1-87-3-2-2-83-3 455 15 (38.5) 10 (66.7) 2 (13.3) 3 (20) 0 (0) 0 (0) 13 (86.7) 13/15 (86.7)
544/2 1-87-3-2-2-97-3 455 4 (10.2) 1 (25) 2 (50) 0 (0) 0 (0) 0 (0) 3 (75) 3/4 (75)
545/2 1-12-3-2-2-104-3 545 4 (10.2) 3 (75) 0 (0) 0 (0) 0 (0) 0 (0) 3 (75) 3/4 (75)
208/2 1-3-3-2-2-97-3 92 3 (7.7) 0 (0) 1 (33.3) 0 (0) 0 (0) 0 (0) 3 (100) 1/3 (33.3)
436/2 1-3-3-2-2-103-3 92 2 (5.1) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 2 (100) 1/2 (50)
191/2 1-3-3-2-2-94-3 92 2 (5.1) 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 1 (50) 0/2 (0)
473/2 1-3-3-2-2-99-3 92 2 (5.1) 1 (50) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 1/2 (50)
456/217 11-65-14-20-37-83-15 456 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 1 (100)
546/2 1-3-3-2-2-66-3 92 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
547/2 1-3-3-2-2-157-3 92 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
548/N1 1-15-3-2-2-157-3 d 1 (2.6) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
549/129 18-3-3-2-1-99-4 555 1 (2.6) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (100) 0 (0)
550/129 18-3-3-2-1-157-4 555 1 (2.6) 0 (0) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100) 0 (0)
551/129 18-15-3-2-1-106-4 d 1 (2.6) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0)
ISAB
208/2 1-3-3-2-2-97-3 92 2 (15.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50) 1/2 (50)
552 21-35-2-28-1-145-4 552 2 (15.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 1/2 (50)
485 33-12-59-11-32-158-5 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
546/2 1-3-3-2-2-66-3 92 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
553 21-35-2-28-1-157-4 552 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 1/1 (100)
554 1-31-12-11-4-103-3 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
679 56-100-137-7-51-99-74 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
680 21-101-3-28-32-172-5 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
681 1-102-59-28-1-83-45 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
683 2-38-42-1-1-185-49 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Data are presented as n (%) or n/N (%).
IRAB Z imipenem-resistant A. baumannii; ISAB Z imipenem-susceptible A. baumannii; MLST, multilocus sequence typing; VAP Z ventilation-associated pneumonia; B/P = Bartual’s
PubMLST and Pasteur’s MLST.
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Table 2 Sequence types (ST), allelic profiles, clonal complex (CC), imipenem resistance genes, and attributable mortality of
Acinetobacter baumannii derived from patients with ventilator-associated pneumonia caused by IRAB (the upper part) or ISAB
(the lower part).
ST (B/P) Allelic profiles CC No. of
isolates
Carbapenem resistance genes Mortality
Tn2006 Tn2008 ISAba1eblaOXA-51 ISAba3e
blaOXA-58eISAba3
blaIMP
IRAB
455/2 1-87-3-2-2-83-3 455/2 11 (45.8) 10 (90.9) 1 (9.1) 0 (0) 0 (0) 0 (0) 3/11 (27.3)
544/2 1-87-3-2-2-97-3 455/2 4 (16.7) 4 (100) 0 (0) 0 (0) 0 (0) 0 (0) 2/4 (50)
208/2 1-3-3-2-2-97-3 92/2 2 (8.3) 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 1/2 (50)
556/N2 1-12-3-2-2-144-3 545 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1/1 (100)
456/217 11-65-14-20-37-83-15 456 1 (4.2) 0 (0) 0 (0) 0 (0) 1 (100) 1 (100) 1/1 (100)
473/2 1-3-3-2-2-99-3 92/2 1 (4.2) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
545/2 1-12-3-2-2-104-3 545/2 1 (4.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
555/129 18-3-3-2-1-144-4 555 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
673/129 18-3-3-2-1-144-73 555 1 (4.2) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
676/2 1-3-3-2-2-184-3 92/2 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ISAB
436 1-3-3-2-2-103-3 92 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
556 1-12-3-2-2-144-3 545 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
674 11-20-14-20-37-83-15 456 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
675 11-65-14-21-37-83-15 456 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
677 55-65-136-65-27-172-57 d 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
678 26-99-43-20-25-83-28 d 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Data are presented as n (%) or n/N (%).
IRAB Z imipenem-resistant A. baumannii; ISAB Z imipenem-susceptible A. baumannii.
592 H.-Y. Lee et al.isolate with blaOXA-58. The isolate with ISAba3eblaOXA-58
also carried ISAba3 in the downstream and showed high-
level resistance to imipenem (MIC  16 mg/L). This
isolate belonged to ST456. One isolate belonging to ST456
harbored blaIMP-1 that offered all these isolates with high-
level resistance to imipenem as well. None of the isolates
carried blaOXA-40/blaOXA-24, blaIMP-2, blaVIM-1, blaVIM-2, or
blaNDM-1, blaADC, ISAba2, IS1008, or Tn2007 (ISAba4e-
blaOXA-23).
There was no significant difference in the number of
isolates carryingTn2006 between blood and sputum IRAB
(25/39 vs. 18/24, p Z 0.416). Similar results were also
found in other carbapenem resistance genes (all p > 0.05).Clinical outcomes
Among 34 patients with ST2P infection (87.2% of IRAB), 15
infected by ST455B/ST2P had higher attributable mortality
(p Z 0.026), higher Acute Physiology and Chronic Health
Evaluation II (APACHE II) score (p Z 0.040), higher Pitt
bacteremia score (p Z 0.032), and longer ICU stay
(p Z 0.014) than 19 patients with non-ST455B/ST2P infec-
tion (Table 3).
In multivariate logistic regression analysis for mortality
of the patents, infection by ST455B and inappropriate initial
antimicrobial therapy were statistically significant risk
factors for mortality (Table 4). For IRAB bacteremia, pa-
tients given appropriate therapy (early effective antibiotics
administered in 2 days) had a lower mortality (31.2%) than
those given inappropriate therapy (late therapy or therapywith ineffective agents; 82.6%; p Z 0.002). The mean
culture reporting time was 3 days.
Patients with IRAB bacteremia showed higher mortality
(26/39, 66.7%) than those with ISAB bacteremia (3/13,
23.1%; p Z 0.009). Patients with IRAB bacteremia showed
higher mortality (26/39, 66.7%) than those with only IRAB
pneumonia (8/24, 33.3%; p Z 0.018). Patients with ST455
bacteremia showed higher mortality (13/15, 86.7%) than
those with non-ST455 bacteremia (16/37, 43.2%;
p Z 0.005).
Discussion
Although the Pasteur scheme was considered to be the gold
standard of the MLST method in typing A. baumannii,6 we
found in this study that ST455B/ST2P can only be differen-
tiated from non-ST455B/ST2P by using the Bartual scheme.
ST455B was first reported in Taiwan, but it has been re-
ported to be the predominant clone among A. baumannii
isolates collected from 12 hospitals throughout Japan.20
ST455 also appeared in southern Taiwan (C.H. Chiu, un-
published data). As the population structure of A. bau-
mannii seems to be highly diverse,21 it is important to use
an MLST scheme with a higher level of resolution to identify
any tiny but significant difference. In our study, nine
different STs (ST455, ST544, ST545, ST208, ST436, ST191,
ST473, ST546, and ST547) by the Bartual scheme could not
be differentiated using the Pasteur scheme, and thus all
these nine different STP belonged to ST2B. However,
ST455B/ST2P infection showed a significantly higher attrib-
utable mortality than non-ST455B/ST2P (Table 3). The
Figure 1. Population snapshot of 82 Acinetobacter baumannii isolates derived from patients in this study. Current existing clones
in Bartual’s PubMLST database analyzed by eBURST algorithm are shown. The radial diagram reflects the predicted evolutionary
descent from sequence type (ST) of the founder. A circle represents an ST, and its size corresponds to the number of isolates. CC92
included ST208 with its derivative STs (ST191, ST436, ST473, ST546, ST547, and ST676). Novel CC455, including ST455 and ST544,
have a double-locus-variant relationship with ST92 and derived from CC92 following the evolutionary line from ST208 to ST455. In
addition to CC455, four other new clonal complexes (CC456, CC545, CC552, and CC555) descent from ST456, ST545, ST552, and
ST555 were also found and newly named by this study.
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Bartual scheme rather than the Pasteur scheme. All
ST455B/ST2P isolates were collected from patients in ICUs
in our hospital during a 12-month period. We have observed
no temporal or geographic association among these iso-
lates. No outbreak was found. By contrast, PFGE genotypes
1e7 could only be differentiated by different MLST geno-
types using the Bartual scheme rather than the Pasteur
scheme.
Although the Bartual scheme was an important MLST
method for genotyping A. baumannii worldwide,4,6 no data
were found with this method in Taiwan. Fifteen isolates in
2006 was analyzed using only the Pasteur scheme in Taiwan
Surveillance of Antimicrobial Resistance study, and all
belonged to ST2P.22 In the other study, a total of 19 MLST
types defined by the Pasteur scheme were found among the
87 isolates examined in 2010.23 The predominant MLST
genotype, ST2P, was identified in 42 isolates and ST129P in
25 isolates.23 Likewise, ST2P and ST129P were the major STs
in isolates in this study. Again, the Bartual scheme has
never been used in previous studies, and identification of
novel, clinically significant STs using the Bartual scheme
was not possible in previous as well as current studies.22,23
Most isolates in this study belonged to CC92 B/CC2P,
which is currently the most prevalent clonal complexworldwide.6,24 Currently, most clinical isolates in Asia,
United States, and Australia belonged to CC92 and carried
blaOXA-23.
25e29 AbaR4-type resistance islands that carried
blaOXA-23 were detected in IRAB isolates from most Asian
countries.25 In China, ST92 was the most prevalent clone
and was found in every province in that country.26,27 It is
apparent that the reason for the rapidly increasing carba-
penem resistance in China was the wide dissemination of
imipenem-resistant, blaOXA-23-like-producing CC92, espe-
cially ST92, ST75, and ST138.27 By contrast, carbapenem-
susceptible isolates in China had a more diverse genetic
background.27 In the United States, ST122 and ST208 were
the most common and were found in four of the six hos-
pitals surveyed in previous studies.28,29 Carbapenemase-
encoding genes blaOXA-23 and/or ISAba1-blaOXA-51-like were
present among the majority of these isolates. First re-
ported in Pittsburgh, St. Louis, Los Angeles, and Las Vegas
in the United States between 2008 and 2009,28 ST208 was
the founder of our isolates belonging to CC92. ST208 was
also found in Denmark,30 Egypt, and China (http://
pubmlst.org/abaumannii/). In Australia, most clinical iso-
lates of A. baumannii also belonged to ST92 and carried
blaOXA-23.
24
IRAB appeared more diverse in South America.31e33
However, blaOXA-23-like gene and AbaR-type genomic
Table 3 Comparison of clinical presentations of patients with ST455B/ST2P infections and those with non-ST455B/ST2P
infectionsa among the study population of all patients with bloodstream IRAB ST2P infections.
Characteristic Patients with ST455B/ST2P
(n Z 15)
Patients with non-ST455B/ST2P
(n Z 19)
p
Demographic characteristics
Age (y) 64.8  18.1 66.6  18.0 0.930
Male 7 (46.7) 11 (57.9) 0.516
Length of stay in hospital 32.3  26.8 24.3  19.8 0.327
Length of stay in ICU (d) 12.1  4.3 8.8  3.0 0.014
Underlying diseases
Charlson score 3.7  2.7 4.1  3.0 0.700
Neoplastic diseaseb 7 (46.7) 11 (57.9) 0.516
Metastatic malignancyb 3 (20.0) 4 (21.1) 0.940
Cardiac disease 3 (20.0) 6 (31.6) 0.451
Cerebrovascular disease 1 (6.7) 4 (21.1) 0.264
Diabetes 5 (33.3) 1 (5.3) 0.059
Pulmonary disease 3 (20.0) 2 (10.5) 0.445
Hepatic disease 1 (6.7) 2 (10.5) 0.696
Renal disease 7 (46.7) 7 (36.8) 0.564
Peptic ulcer 1 (6.7) 5 (26.3) 0.165
Clinical severity
APACHE II score 26.6  4.7 23.0  5.0 0.040
Pitt bacteremia score 5.7  1.9 4.2  2.0 0.032
Attributable mortality 13 (86.7) 9 (47.3) 0.026
Inappropriate initial therapy 10 (66.7) 11 (57.9) 0.827
a Isolates of non-ST455B/ST2P are those belonging to ST2 in the Pasteur scheme but not ST455 in the Bartual scheme. They belonged to
ST544, ST545, ST208, ST436, ST191, ST473, ST546, and ST547 in the Bartual scheme.
b Neoplastic disease included metastatic malignancy and other primary neoplastic diseases.
Data are presented as mean  SD or n (%).
APACHE II Z Acute Physiology and Chronic Health Evaluation II; ICU Z intensive care unit; IRAB Z imipenem-resistant Acinetobacter
baumannii; ST Z sequence type; MLST, multilocus sequence typing; ST Z sequence type; VAP Z ventilator-associated pneumonia.
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different CCs. In Brazil, CC104, CC109, and CC113 were
found as predominant clones.33 Most IRAB isolates (72%)
carried the blaOXA-23-like gene in Brazil.
31 CC104 and CC113Table 4 Logistic regression analysis of risk factors for mortality
Characteristic Nonsurvivors
(n Z 24)
Survivors
(n Z 15)
U
O
MLST genotypes
ST455B 13 (54.2) 2 (13.3)
ST2P 22 (91.7) 13 (86.7)
Demographic characteristics
Age (y) 64.4  17.6 68.9  20.0
Male 13 (54.1) 10 (66.7)
Underlying diseases
Charlson score 3.62  2.90 3.60  2.67 1
Clinical severity
APACHE II score 24.0  5.2 22.1  4.5
Pitt bacteremia score 5.3  1.9 4.0  2.2
Inappropriate initial therapy 18 (79.2) 4 (26.7) 1
Data are presented as mean  SD or n (%).
*All variables with a p value < 0.20 in the univariate analysis were c
multivariate analysis. A forward stepwise selection process was used
therapy were statistically significant risk factors for mortality.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; CI Z
baumannii.were also found to be common in Argentina. AbaR-type
genomic islands have been detected in most multidrug-
resistant A. baumannii isolates (36/51) in Argentina,
Uruguay, and Chile since 1986.32 CC113, CC103, and ST25of patents with bloodstream IRAB infection.
nivariate analysis p Multivariate analysis* p
dds ratio (95% CI) Odds ratio (95% CI)
7.68 (1.42e41.69) 0.018 11.26 (1.45e87.78) 0.021
2.75 (0.40e18.80) 0.302
0.99 (0.95e1.02) 0.456
0.59 (0.16e2.26) 0.442
.003 (0.79e1.27) 0.978
1.18 (1.02e1.37) 0.030
1.39 (0.99e1.95) 0.058
0.45 (2.31e47.30) 0.002 14.31 (2.34e87.57) 0.004
onsidered to be included in the logistic regression model in the
. We found that only infection by ST455 and inappropriate initial
confidence interval; IRAB Z imipenem-resistant Acinetobacter
Emergence of imipenem-resistant A. baumannii ST455 595were the major clones in Buenos Aires and Rosario, and
most of these clones carried blaOXA-23-like.
33
We identified 26 novel STB and five novel CCB in this study.
Novel ST455B, contributing to 38.5% of IRAB bacteremia,
resulted in 86.7% attributable mortality in a cohort of pa-
tients. A possible explanation for the successful spread of
ST455 in the hospitals is that they have a selective advantage
over other strains. Antimicrobial resistance is one such
advantage, and we found that all of ST455 isolates showed
high imipenem resistance (MIC > 16 mg/L) as well as resis-
tance to all other tested antibiotics except colistin and
tigecycline. In addition to 33.3% isolates carrying Tn2008 or
ISAba1eblaOXA-51, 66.7% of ST455 bloodstream isolates car-
riedTn2006 in an AbaR4-type resistance island. It is difficult
to give effective antibiotics for treating ST455 infection in 2
days prior to culture reporting (mean, 3 days). No adminis-
tration of appropriate drugs in time apparently resulted in
high mortality among patients infected by ST455. This clone
might become a threat to public health because higher
attributable mortality, higher APACHE II score, and higher
Pitt bacteremia score were found from patients with
ST455B/ST2Pinfection. Increased virulence of this clone
deduced from this result warrants further studies.
The majority of IRABST455 isolates showed a common
imipenem resistance genetic determinant, ISAba1eblaOXA-
23eISAba1 (Tn2006), located in an AbaR4-type resistance
island. Our previous study indicated that in Taiwan this
transposon had become the most common carbapenem
resistance gene in A. baumannii since 2009 and has
replaced ISAba1eblaOXA-51, the predominant resistance
mechanism from 1993 to 2007.17,19
ST455 bacteremia appeared to originate from VAP based
on three findings of this study: first, > 85% of ST455
bacteremia had a primary source of VAP; second, no sig-
nificant difference was found in the distribution of STs and
carbapenemase genes between blood isolates from
bacteremic patients and sputum isolates from patients with
VAP; and third, all three paired isolates from blood and
sputum of the same patients showed the same MLST and
PFGE genotype, including two patients infected by ST455
(PFGE type 1) and one by ST544 (PFGE type 2).
In conclusion, A. baumannii has become the most com-
mon pathogen for nosocomial bloodstream infection in ICUs
in Taiwan since 2009.19 ST455B/ST2P, the predominant clone
of IRAB identified in this study, has been posing a significant
threat to patients’ health and has the potential to cause a
regional or global spread, given its highly pathogenic and
resistant nature. Continued surveillance is necessary. It is
also important to detect and use effective drugs to treat
ST455B/ST2P infection earlier at the stage of VAP rather than
in bacteremic stage to decrease the mortality rate.Conflicts of interest
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